H.C. Wainwright Starts Clearside Biomedical (CLSD) at Buy
- Dow, S&P 500 end with gains up after bumpy week, but Nike drags
- Over $100 Billion Wiped Off: Bitcoin (BTC) Price Falls As China's Central Bank Vows to Ban Cryptocurrency Trading
- Nike (NKE) Stock Falls On a Revenue Miss and Slashed FY Sales Outlook, Analysts Bullish Despite NT Supply Chain Challenges
- Oil hits highest in almost 3 years as supply tightens
- Here's Why Meredith (MDP) Stock Price Soared 18% in After Hours
H.C. Wainwright analyst Yi Chen initiates coverage on Clearside Biomedical (NASDAQ: CLSD) with a Buy rating and a price target of $10.00.
Shares of Clearside Biomedical closed at $5.12 yesterday.
You May Also Be Interested In
- Summit Insights Assumes ServiceNow (NOW) at Buy
- JPMorgan Starts Sinopec Shanghai Petrochemical (600688:CH) (SHI) at Neutral
- UBS Starts Shenzhen Sunlord Electronics (002138:CH) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!